camptothecin has been researched along with Glial Cell Tumors in 150 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (10.67) | 18.2507 |
| 2000's | 66 (44.00) | 29.6817 |
| 2010's | 62 (41.33) | 24.3611 |
| 2020's | 6 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furbacher, TR; Gunatilaka, AA | 1 |
| Alderson, LM; Amundson, E; Brem, H; Colvin, M; Sampath, P; Tyler, BM; Wall, ME; Wani, MC; Weingart, JD | 1 |
| Chen, M; Wang, X; Wang, Z; Yu, H | 1 |
| Andre, N; Beccaria, K; Bertozzi, AI; Boddaert, N; Bourdeaut, F; Butel, T; Cuinet, A; De Carli, E; de Marcellus, C; Dufour, C; Figarella-Branger, D; Fouyssac, F; Grill, J; Leblond, P; Pasqualini, C; Puget, S; Robert, MP; Tauziède-Espariat, A; Valteau-Couanet, D; Varlet, P | 1 |
| Cai, K; Dai, L; Fu, T; He, Y; Li, K; Lu, L; Luo, Z; Zeng, R; Zhao, X | 1 |
| Chen, N; Liu, G; Qian, Y; Wang, X; Wu, J; Yu, Y; Zhang, J; Zhang, L; Zhou, D | 1 |
| Kanazawa, T; Okada, H; Taki, H | 1 |
| Chen, M; Chu, X; Cui, Y; Fan, Y; Gao, C; Hao, W; Wang, Y; Yang, Y | 1 |
| Chi, SN; Cohen, KJ; DiRenzo, J; Donson, AM; Dunkel, IJ; Etzl, MM; Foreman, NK; Gore, L; Kieran, MW; Kuei, MC; MacDonald, TJ; Macy, ME; Narendran, A; Ostrovnaya, I; Smith, AA; Trippett, TM | 1 |
| Jiang, X; Li, C; Liang, L; Liu, L; Lu, P; Qiao, Y; Wang, L; Xia, Y; Yang, T | 1 |
| Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Larsen, VA; Lassen, U; Lukram, B; Michaelsen, SR; Poulsen, HS; Toft, A; Urup, T | 1 |
| Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X | 1 |
| Blaum, M; Galldiks, N; Heinzel, A; Langen, KJ; Mottaghy, FM; Müller, D; Verburg, FA | 1 |
| Ferreira, DC; Lúcio, M; Martins, SM; Nunes, C; Reis, S; Sarmento, B | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Blüml, S; Brown, RJ; Dhall, G; Finlay, JL; Wellner, M; Zaky, W | 1 |
| Aboody, KS; Abramyants, Y; Barish, ME; Brown, CE; Ghoda, LY; Gilchrist, M; Gutova, M; Lacey, SF; Metz, MZ; Najbauer, J; Portnow, J; Potter, PM; Synold, TW; Tirughana, R; Vo, T | 1 |
| Banerjee, A; Boyett, JM; Fahey, F; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Vajapeyam, S; Wu, S | 1 |
| Cloughesy, TF; Dahlbom, M; Huang, SC; Phelps, ME; Schiepers, C; Wardak, M | 1 |
| Kanazawa, T; Morisaki, K; Suzuki, S; Takashima, Y | 1 |
| Chow, L; DeWire, M; Fouladi, M; Goldman, S; Hummel, T; Lane, A; Leach, J; Miles, L; Salloum, R; Stevenson, C; Sutton, M | 1 |
| Berens, ME; Chung, EP; Dhruv, HD; DiPerna, DM; Householder, KT; Sirianni, RW; Wohlleb, GM | 1 |
| Bhardwaj, RD; Nakaji, P; Ponce, FA; Rosenfeld, A; Xu, DS | 1 |
| Chen, TC; Golden, EB; Gong, A; Hofman, FM; Howard, A; Jhaveri, N; Louie, SG; Schönthal, AH; Sivakumar, W; Torres, S; Vaikari, VP; Wang, W | 1 |
| Ames, MM; Berg, AK; Buckner, JC; Galanis, E; Jaeckle, KA; Reid, JM | 1 |
| Dalla Pozza, L; Heath, JA; Kalra, M; Kellie, SJ; McCowage, GB; Stevens, MM; Swamy, S | 1 |
| Kanamori, M; Kawashima, R; Mano, Y; Saito, R; Sonoda, Y; Sumiyoshi, A; Tominaga, T; Zhang, R | 1 |
| Cheng, CJ; Deng, Y; Quijano, E; Saltzman, WM; Saucier-Sawyer, JK; Seo, YE; Zhang, J | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Backus, L; Chow, LM; DeWire, M; Doughman, R; Drissi, R; Fouladi, M; Goldman, S; Grimme, L; Hummel, TR; Kumar, S; Lane, A; Leach, J; Miles, L; Pai, A; Pruitt, D; Salloum, R; Sobo, M; Stevenson, C; Sutton, M | 1 |
| Al-Ghafari, AB; Carrier, DJ; Coyle, B; Hussein, D; Kerr, ID; Punjaruk, W; Storer, LC | 1 |
| André, N; Dory-Lautrec, P; Figarella-Branger, D; Gentet, JC; Heng, MA; Padovani, L; Pasquier, E; Scavarda, D; Verschuur, A | 1 |
| Cha, Y; Choi, B; Choi, SH; Heo, DS; Kim, CY; Kim, DW; Kim, E; Kim, IA; Kim, IH; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Park, CK | 1 |
| Chen, RM; Lin, CJ; Lin, YL; Luh, F; Yen, Y | 1 |
| Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R | 1 |
| Huang, YC; Lee, WH; Liu, SC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, ST | 1 |
| Barrie, M; Boucard, C; Campello, C; Chinot, O; Farina, P; Girard, N; Graillon, T; Lehmann, P; Petrirena, G; Tabouret, E | 1 |
| Batchelor, T; Carson, KA; Grossman, SA; Hausheer, F; Lesser, G; Nabors, LB; Peereboom, D; Phuphanich, S; Supko, JG | 1 |
| Desjardins, A; Friedman, HS; Reardon, DA; Vredenburgh, JJ | 1 |
| Drappatz, J; Norden, AD; Wen, PY | 1 |
| Anderson, J; Doyle, T; Ellika, S; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; Quinn, JA; Reardon, DA; Rich, JN; Sampson, J; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Delattre, JY; Omuro, AM | 1 |
| David, K; Drappatz, J; Gerard, M; Kesari, S; McNamara, MB; Muzikansky, A; Norden, AD; Phan, P; Ross, A; Wen, PY | 1 |
| Ames, MM; Buckner, JC; Felten, SJ; Galanis, E; Jaeckle, KA; Nikcevich, DA; Reid, JM; Santisteban, M; Scheithauer, BW; Wiesenfeld, M; Wu, W | 1 |
| Loutfi, R; Mikkelsen, T; Torcuator, R; Zuniga, R | 1 |
| Cohen, B; Fisher, MJ; Horn, M; Jakacki, R; MacDonald, T; Packer, RJ; Rood, B; Vezina, G | 1 |
| Koga, Y; Kuratsu, J; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M | 1 |
| Chen, H; Qian, YH; Xiao, Q; Xu, J | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Alonso, MM; Bhat, KP; Colman, H; Fueyo, J; Gomez-Manzano, C; Gumin, J; Lang, FF; Lee, OH; Liu, D; Martin, V; Pabbisetty, SK; Xu, J | 1 |
| Colman, H; Conrad, CA; Emmett, MR; He, H; Ji, Y; Kroes, RA; Lang, FF; Marshall, AG; Moskal, JR; Nilsson, CL | 1 |
| Chen, BS; Cui, Y; Jiang, T; Li, SW; Qiu, XG; Ren, H; Zhang, W | 1 |
| Ishikawa, E; Kamiyama, H; Mashiko, R; Matsumura, A; Osuka, S; Takano, S | 1 |
| Anderson, J; Doyle, T; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Baltes, S; Brinker, T; Freund, I; Lewis, AL; Nolte, I | 1 |
| Allen, J; Chacko-Mathew, J; Gardner, S; Harter, D; Karajannis, M; Kunnakkat, S; Narayana, A; Raza, S; Weiner, H; Wisoff, J | 1 |
| Hattermann, K; Held-Feindt, J; Lucius, R; Mentlein, R; Müerköster, SS; Penfold, ME; Schall, TJ | 1 |
| Chen, TC; Ghandi, A; Hofman, FM; Liebes, L; Louie, SG; Schönthal, AH; Wang, W | 1 |
| Boyett, JM; Chi, SN; Friedman, HS; Gilbertson, RJ; Gururangan, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Rood, BN; Vajapeyam, S; Young Poussaint, T | 1 |
| Bankiewicz, KS; Berger, MS; Bringas, JR; Dickinson, PJ; Drummond, DC; Forsayeth, J; Higgins, RJ; Kirpotin, DB; Krauze, MT; Larson, RF; LeCouteur, RA; Noble, CO; Park, JW; Yamashita, Y | 1 |
| Chen, J; Lu, Y; Wolff, JE; Xu, T | 1 |
| Angelastro, JM; Lamé, MW | 1 |
| Hashizawa, K; Imai, Y; Kaneko, D; Okada, H; Ozeki, T | 1 |
| Allard, E; Benoit, JP; Bilensoy, E; Calış, S; Cırpanlı, Y; Lemaire, L; Passirani, C | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Goebel, G; Gotwald, T; Güler, O; Hutterer, M; Kostron, H; Nowosielski, M; Recheis, W; Schocke, M; Stockhammer, G; Tinkhauser, G | 1 |
| Dumble, M; Greenberger, LM; Horak, ID; Kraft, P; Mehlig, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P; Wang, M | 1 |
| Gotwald, T; Hutterer, M; Jacobs, AH; Kostron, H; Muigg, A; Nowosielski, M; Putzer, D; Staffen, W; Stockhammer, G; Tinkhauser, G; Trinka, E; Virgolini, IJ; Waitz, D | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Chan, RT; Fung, CF; Hung, KN; Leung, GK; Ng, GK; Pu, JK | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Dahlbom, M; Huang, SC; Phelps, ME; Satyamurthy, N; Schiepers, C; Wardak, M | 1 |
| Brinker, T; Glage, S; Hedrich, HJ; Held, N; Lewis, AL | 1 |
| Desjardins, A; Sampson, JH | 1 |
| Cho, BK; Kim, CY; Kim, SK; Lee, SJ; Park, CK; Wang, KC | 1 |
| Baltes, S; Brinker, T; Geigle, P; Glage, S; Lewis, AL; Mertens, P | 1 |
| Hashizawa, K; Imai, Y; Kaneko, D; Okada, H; Ozeki, T; Tagami, T | 2 |
| Barrie, M; Bequet-Boucard, C; Chinot, O; Colavolpe, C; Figarella-Branger, D; Guedj, E; Mancini, J; Metellus, P; Mundler, O; Tabouret, E | 1 |
| Carrillo, JA; Munoz, CA | 1 |
| Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G | 1 |
| Matsko, MV | 1 |
| Beckta, JM; Valerie, K; Wagner, AF; Wynne, KJ; Yang, H; Zolotarskaya, OY | 1 |
| Happold, C; Hundsberger, T; Seystahl, K; Weller, M; Wick, A; Wick, W; Wiestler, B | 1 |
| Akman, T; Aktas, B; Alacacioglu, A; Balakan, O; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Engin, H; Gunaydin, Y; Harputluoglu, H; Kaplan, MA; Karaca, H; Ozdemir, NY; Sevinc, A; Sonmez, OU; Tonyali, O; Tufan, G; Tugba Unek, I | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Fouladi, M; Gajjar, A; Heideman, RL; Houghton, PJ; Jones-Wallace, D; Stewart, CF; Thompson, SJ | 1 |
| Melillo, G; Rapisarda, A; Sausville, EA; Scudiero, DA; Selby, M; Shoemaker, RH; Uranchimeg, B | 1 |
| Kuhn, JG | 1 |
| Arizono, Y; Hamada, Y; Naganuma, H; Nakajima, Y; Tasaka, K; Yoshikawa, H | 1 |
| Baldwin, AS; Cusack, JC; Ewend, MG; Weaver, KD; Yeyeodu, S | 1 |
| Ames, M; Buckner, JC; Cha, S; Erlichman, C; Kaufmann, SH; Miller, LL; O'Fallon, JR; Reid, JM; Schaaf, LJ; Wright, K | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Gajjar, A; Jones-Wallace, D; Stewart, CF | 1 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Kuhn, J; Miller, LL; Nelson, G | 1 |
| Friedman, HS; Gilbert, M; Powell, JB; Reardon, DA; Yung, WK | 1 |
| Batchelor, T; Fisher, JD; Gilbert, MR; Grossman, S; Lesser, G; Piantadosi, S; Supko, JG | 1 |
| Beaudry, CE; Berens, ME; Demuth, T; Holz, DR; Joy, AM; Ponce, FA; Tran, NL | 1 |
| Buster, WP; Gruber, ML | 1 |
| Batchelor, TT; Carson, KA; Gilbert, MR; Grossman, SA; Lesser, GJ; Mikkelsen, T; Nabors, LB; Phuphanich, S; Supko, JG | 1 |
| Chang, SM; Cloughesy, TF; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Cloughesy, T; Filka, E; Fruehauf, JP; Mehta, R; Parker, RJ | 1 |
| Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Blank, A; Bobola, MS; D Kolstoe, D; Gold, B; Loeb, LA; Meade, EH; Rabinovitch, PS; Silber, JR; Varadarajan, S | 1 |
| Dwarakanath, BS; Khaitan, D; Ravindranath, T | 1 |
| Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D | 1 |
| Kamiyama, H; Matsumura, A; Takano, S; Tsuboi, K | 1 |
| Chen, AY; Curran, DP; Garriques, LN; Hsiao, M; Rothenberg, ML; Shih, SJ | 1 |
| Chiocca, EA; Danks, MK; Finkelstein, DM; Hyatt, JL; Leroy, S; Potter, PM; Saeki, Y; Terada, K; Tyminski, E | 1 |
| Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J | 1 |
| Hasegawa, Y; Ishikawa, K; Kajita, Y; Nabeshima, T; Noda, Y; Yoshida, J | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Houghton, PJ; Iacono, LC; Kocak, M; Krasin, MJ; Kun, LE; Ledet, D; Merchant, TE; Stewart, CF | 1 |
| Arimochi, H; Morita, K | 1 |
| Hegi, ME; Stupp, R; van den Bent, MJ | 1 |
| Chang, S; Cloughesy, T; Fine, HA; Fink, K; Greenberg, H; Hess, K; Jaeckle, K; Junck, L; Kuhn, J; Lamborn, K; Mehta, M; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Cloughesy, TF; Lai, A; Mischel, P; Nghiemphu, P; Pope, WB | 1 |
| Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A | 1 |
| Feun, LG; Heros, D; Herrera, C; Landy, H; Marini, A; Markoe, A; Robles, C; Savaraj, N | 1 |
| Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ; Wagner, M | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Delaloye, S; Geist, C; Lai, A; Phelps, ME; Pope, W; Satyamurthy, N; Sayre, J; Silverman, DH | 1 |
| Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK | 1 |
| Blumenthal, DT; Bokstein, F; Shpigel, S | 1 |
| Elinzano, H; Jin, T; Kang, TY; Peereboom, D | 1 |
| Beckman, EJ; Petoud, S; Pollack, IF; Sivak, WN; Zamboni, WC; Zhang, J | 1 |
| Friedman, HS; Malone, S; Petros, WP; Schaaf, LJ; Younis, IR | 1 |
| Fujiwara, T; Matsumoto, Y; Nagao, S | 1 |
| Fujiwara, T; Honjo, Y; Matsumoto, Y; Nagao, S; Sasaoka, N; Tsuchida, T | 2 |
| Bjornsti, MA; Chang, CF; Gordon, J; Kerr, DA; Khalili, K | 1 |
| Adamson, PC; Allen, JC; Balis, FM; Berg, SL; Blaney, SM; Heideman, RL; Horowitz, ME; Jakacki, RI; Lange, BJ; Packer, RJ; Phillips, PC; Poplack, DG; Reaman, GH; Sallan, SE | 1 |
| Boothman, DA; Lamond, JP; Mehta, MP | 1 |
| Dichgans, J; Esser, P; Fontana, A; Groscurth, P; Schmidt, C; Weller, M; Winter, S | 1 |
| Bigner, DD; Coggins, CA; Colvin, OM; Elion, GB; Friedman, HS; Hare, CB; Houghton, PJ; Keir, S | 1 |
| Danks, MK; Morton, CL; Naeve, CW; Pawlik, CA; Potter, PM | 1 |
| Burton, E; Prados, M | 1 |
| Ashley, D; Bigner, DD; Cloughsey, T; Cokgor, I; Colvin, OM; Elfring, GL; Friedman, AH; Friedman, HS; Haglund, M; Houghton, PJ; Kerby, T; Lawyer, J; Lovell, S; Malczyn, J; McLendon, RE; Miller, LL; Parry, M; Petros, WP; Provenzale, JM; Rasheed, K; Rich, J; Schaaf, LJ; Stewart, ES | 1 |
| Ciesielski, MJ; Fenstermaker, RA | 1 |
| Lad, TE; Minami, H; Nicholas, MK; Ratain, MJ; Vokes, EE | 1 |
| Aguzzi, A; Dichgans, J; Pohl, U; Steinbach, JP; Weissenberger, J; Weller, M; Wick, W | 1 |
| Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT | 1 |
| Bartussek, C; Naumann, U; Weller, M | 1 |
| Bigner, DD; Castellino, RC; Elion, GB; Friedman, HS; Houghton, PJ; Johnson, SP; Keir, ST | 1 |
| Fung, KM; Geoerger, B; Janss, AJ; Kerr, K; Phillips, PC; Powell, B; Sutton, LN; Tang, CB | 1 |
| Janss, AJ; Maity, A; McKenna, WG; Muschel, RJ; Phillips, PC; Sutton, L; Tang, CB | 1 |
| Prados, M | 1 |
| Kherfellah, D; Montaudon, D; Pavillard, V; Richard, S; Robert, J | 1 |
| de Bruijn, EA; Dumez, H; Mathijssen, RH; Sparreboom, A; van Oosterom, AT | 1 |
| Beason, R; Bottom, K; Eastwood, J; Friedman, AH; Friedman, HS; Gururangan, S; McLendon, RE; Miller, LL; Tourt-Uhlig, S; Turner, CD; Watral, M | 1 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Miller, LL; Nelson, G | 1 |
10 review(s) available for camptothecin and Glial Cell Tumors
| Article | Year |
|---|---|
Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Glioma; Humans; Irinotecan; Neoplasm Grading; Neoplasm Recurrence, Local; Prevalence; Survival Rate | 2018 |
Experience with irinotecan for the treatment of malignant glioma.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioma; Humans; Irinotecan; Topoisomerase I Inhibitors | 2009 |
Antiangiogenic therapy in malignant gliomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Disease-Free Survival; Glioma; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Neoplasm Metastasis; Quality of Life; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Evidence-Based Medicine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cisplatin; Glioma; Humans; Irinotecan; Nitrosourea Compounds | 2012 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
Irinotecan: promising activity in the treatment of malignant glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Glioma; Humans; Irinotecan; United States | 2003 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temozolomide | 2006 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
35 trial(s) available for camptothecin and Glial Cell Tumors
| Article | Year |
|---|---|
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pilot Projects; Pyridines; Treatment Outcome | 2017 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Temozolomide; Treatment Outcome | 2013 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Drug Interactions; Enzyme Induction; Female; Glioma; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Phenobarbital; Phenytoin | 2015 |
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2009 |
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis | 2008 |
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Glucuronides; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Glioma; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Immunohistochemistry; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Young Adult | 2009 |
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Brain Stem Neoplasms; Camptothecin; Child; Diffusion Magnetic Resonance Imaging; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Phosphorylation; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Young Adult | 2011 |
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Topoisomerase I Inhibitors | 2002 |
Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.
Topics: Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Multidrug Resistance-Associated Protein 2; Phenytoin; Probability; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Recurrence; Time Factors | 2003 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
Topics: Adult; Brain Neoplasms; Camptothecin; Confidence Intervals; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate | 2004 |
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Statistics, Nonparametric | 2004 |
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Confidence Intervals; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Oligodendroglioma | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 2004 |
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Brain Neoplasms; Camptothecin; Celecoxib; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Infusions, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Pyrazoles; Risk Assessment; Statistics, Nonparametric; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Temozolomide; Treatment Outcome | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Epilepsy; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2006 |
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Teniposide; Tomography, X-Ray Computed | 2007 |
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2007 |
Phase II evaluation of topotecan for pediatric central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Infant; Infusions, Intravenous; Male; Topotecan | 1996 |
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 1999 |
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Glioma; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged | 1999 |
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioblastoma; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Topoisomerase Inhibitors | 2002 |
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adult; Antineoplastic Agents; Camptothecin; Central Nervous System Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors | 2002 |
105 other study(ies) available for camptothecin and Glial Cell Tumors
| Article | Year |
|---|---|
Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Catalysis; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Female; Glioma; Humans; Inhibitory Concentration 50; Lung Neoplasms; Methyl Green; Molecular Structure; Plants, Medicinal; Saccharomyces cerevisiae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triterpenes; Tumor Cells, Cultured | 2001 |
Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Carmustine; Cell Division; Drug Screening Assays, Antitumor; Glioma; Humans; Rats; Tumor Cells, Cultured | 2003 |
Glioma-targeted multifunctional nanoparticles to co-deliver camptothecin and curcumin for enhanced chemo-immunotherapy.
Topics: Camptothecin; Cell Line, Tumor; Curcumin; Drug Delivery Systems; Glioma; Humans; Immunotherapy; Multifunctional Nanoparticles; Nanoparticles | 2022 |
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Neoplasm Recurrence, Local; Retrospective Studies; Young Adult | 2022 |
An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy.
Topics: Blood-Brain Barrier; Camptothecin; Cell Line, Tumor; Glioma; Humans; Micelles; Polyethylene Glycols; Prodrugs | 2020 |
Angiopep2-Conjugated Star-Shaped Polyprodrug Amphiphiles for Simultaneous Glioma-Targeting Therapy and MR Imaging.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Carriers; Glioma; Magnetic Resonance Imaging; Micelles; Peptides; Prodrugs; Rats; Rats, Sprague-Dawley; Theranostic Nanomedicine | 2020 |
Nose-to-brain drug delivery system with ligand/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Bombesin; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Carriers; Glioma; Ligands; Male; Micelles; Nanoparticles; Nose; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Rats; Rats, Sprague-Dawley | 2020 |
Cancer Cell Membrane-Coated Nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Membrane; Endocytosis; Female; Glioma; Humans; Male; Mice, Inbred ICR; Nanoparticles; Rats; Suspensions; Tissue Distribution; Treatment Outcome | 2021 |
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Stem Neoplasms; Camptothecin; Cetuximab; Chemoradiotherapy; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Staging; Prognosis; Survival Rate; Young Adult | 2017 |
The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Monte Carlo Method; Neoplasm Grading; Positron-Emission Tomography; Recurrence; Treatment Outcome; Tyrosine | 2013 |
Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain; Brain Neoplasms; Camptothecin; Cell Line; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Inhibitory Concentration 50; Lipids; Macrophages; Male; Nanoparticles; Particle Size; Rats; Rats, Wistar; Scattering, Small Angle; Tissue Distribution | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Radiography; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Topics: Adenoviridae; Animals; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Dose-Response Relationship, Drug; Feasibility Studies; Genetic Vectors; Glioma; Humans; Irinotecan; Mice; Mice, Knockout; Mice, SCID; Neural Stem Cells; Rabbits; Time Factors; Tissue Distribution; Topoisomerase I Inhibitors; Transduction, Genetic; Transfection; Xenograft Model Antitumor Assays | 2013 |
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Infant; Irinotecan; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2014 |
¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Data Interpretation, Statistical; Dideoxynucleosides; Dihydroxyphenylalanine; Female; Glioma; Humans; Irinotecan; Kinetics; Male; Middle Aged; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Recurrence; Tissue Distribution | 2014 |
Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Camptothecin; Cell Line; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Disease Models, Animal; Glioma; Male; MAP Kinase Kinase Kinases; Micelles; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; RNA, Small Interfering | 2014 |
Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Retrospective Studies; Young Adult | 2015 |
Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Drug Carriers; Feasibility Studies; Glioma; Hydrophobic and Hydrophilic Interactions; Injections, Intravenous; Lactic Acid; Mice; Mice, Inbred C57BL; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Survival Rate; Time Factors | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Peduncle; Child; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Infratentorial Neoplasms; Irinotecan; Laser Therapy; Male; Neoplasms, Multiple Primary; Neurofibromatosis 1; Neuroimaging; Optic Nerve Glioma; Supratentorial Neoplasms; Temozolomide | 2015 |
Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Glioma; Humans; Irinotecan; Mice; Platelet Endothelial Cell Adhesion Molecule-1; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retreatment; Retrospective Studies; Salvage Therapy | 2015 |
Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
Topics: Animals; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Drug Delivery Systems; Gadolinium; Glioma; Humans; Irinotecan; Male; Mice; Micelles; Polymers; Rats; Rats, Inbred F344; Rats, Nude | 2016 |
Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Polymers; Tissue Distribution | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Young Adult | 2016 |
Long-term exposure to irinotecan reduces cell migration in glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Glioma; Humans; Irinotecan; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Wound Healing | 2016 |
Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
Topics: Administration, Metronomic; Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Combined Modality Therapy; Disease Progression; Female; Glioma; Humans; Irinotecan; Maintenance Chemotherapy; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retreatment; Retrospective Studies; Vinblastine | 2016 |
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; Young Adult | 2017 |
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Camptothecin; Carbonic Anhydrase IX; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclodextrins; Female; Glioblastoma; Glioma; Humans; Hypoxia; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoconjugates; Nanomedicine; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Polyethylene Glycols; Tight Junctions; Xenograft Model Antitumor Assays | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy, Adjuvant; Re-Irradiation; Retrospective Studies; Temozolomide | 2016 |
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Brain; Brain Neoplasms; Camptothecin; Cisplatin; Disease Models, Animal; Drug Delivery Systems; Ethylnitrosourea; Glioblastoma; Glioma; Humans; Irinotecan; Lactic Acid; Male; Nanofibers; Neurosurgical Procedures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Tumor Burden | 2016 |
Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Retrospective Studies | 2017 |
What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Glioblastoma; Glioma; Humans; Irinotecan | 2008 |
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carbazoles; Clinical Trials as Topic; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2009 |
Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Radiotherapy | 2009 |
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2009 |
Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Capillary Permeability; Cell Line, Tumor; Glioma; Humans; Irinotecan; Mice; Micelles; Xenograft Model Antitumor Assays | 2009 |
Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Dexamethasone; DNA Fragmentation; Glioma; Rats; Receptors, Glucocorticoid; RNA Interference; STAT5 Transcription Factor | 2009 |
Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitory Concentration 50; Irinotecan; Mitoxantrone; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Receptor, TIE-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation | 2009 |
Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.
Topics: Animals; Camptothecin; Cell Line, Tumor; Gangliosides; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Glioma; Glycomics; Humans; Irinotecan; Lipids; Mice; Phosphatidylglycerols; Sulfoglycosphingolipids; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2010 |
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Proliferation; Glioma; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2010 |
Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Delivery Systems; Female; Glioma; Injections, Intralesional; Irinotecan; Male; Microspheres; Pilot Projects; Rats; Survival Analysis | 2010 |
Bevacizumab in recurrent high-grade pediatric gliomas.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Young Adult | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Proliferation; Chemokine CXCL12; Dacarbazine; Enzyme Activation; Estrenes; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioma; Humans; Pyrrolidinones; Receptors, CXCR; Temozolomide | 2010 |
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Implants; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Survival Analysis; Tissue Distribution | 2011 |
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Convection; Disease Models, Animal; Dogs; Drug Delivery Systems; Glioma; Irinotecan; Liposomes; Magnetic Resonance Imaging; Nanoparticles | 2010 |
Overexpression of CD133 promotes drug resistance in C6 glioma cells.
Topics: AC133 Antigen; Animals; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Glioma; Glycoproteins; Male; Neoplastic Stem Cells; Peptides; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2010 |
Treatment of rat brain tumors using sustained-release of camptothecin from poly(lactic-co-glycolic acid) microspheres in a thermoreversible hydrogel.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Glioma; Hydrogel, Polyethylene Glycol Dimethacrylate; Lactic Acid; Male; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Temperature | 2010 |
Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Compounding; Female; Glioma; Lactic Acid; Nanoparticles; Neoplasm Transplantation; Particle Size; Polyesters; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Inbred F344; Surface-Active Agents | 2011 |
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2011 |
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Image Processing, Computer-Assisted; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron-Emission Tomography; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Failure; Tyrosine; Ultrasonography | 2011 |
Using bevacizumab in the fight against malignant glioma: first results in Asian patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asian People; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2011 |
Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radionuclide Imaging | 2011 |
A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cats; Doxorubicin; Female; Glioma; Infusion Pumps, Implantable; Injections, Intraventricular; Irinotecan; Male; Microspheres; Necrosis; Safety; Treatment Outcome | 2011 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Etoposide; Female; Glioblastoma; Glioma; Humans; Male; Neoplasm Recurrence, Local; Salvage Therapy; Supratentorial Neoplasms; Temozolomide | 2012 |
Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Glioma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2012 |
Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.
Topics: Alginates; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Doxorubicin; Drug Delivery Systems; Female; Glioma; Glucuronic Acid; Hexuronic Acids; Irinotecan; Male; Materials Testing; Microspheres; Rats; Survival Rate; Suspensions; Tumor Burden | 2012 |
Improvement of survival in C6 rat glioma model by a sustained drug release from localized PLGA microspheres in a thermoreversible hydrogel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Fluorescein-5-isothiocyanate; Glioma; Hot Temperature; Hydrogels; Lactic Acid; Male; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Vincristine | 2012 |
FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Fluorodeoxyglucose F18; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2012 |
Combination therapy of surgical tumor resection with implantation of a hydrogel containing camptothecin-loaded poly(lactic-co-glycolic acid) microspheres in a C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Drug Implants; Glioma; Hydrogels; Lactic Acid; Male; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide | 2012 |
Synthesis of water-soluble camptothecin-polyoxetane conjugates via click chemistry.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Survival; Click Chemistry; Glioma; Humans; Luciferases; Molecular Structure; Polyethylene Glycols; Polymers; Propylene Glycols; Solubility; Tumor Cells, Cultured; Water | 2012 |
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2013 |
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; DNA, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Gene Expression; Glioma; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Lymphokines; Nuclear Proteins; Promoter Regions, Genetic; Response Elements; RNA, Messenger; Topotecan; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Survival; Cisplatin; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Fibrosarcoma; Flow Cytometry; Glioma; Humans; Membrane Glycoproteins; Osteosarcoma; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Carboplatin; Carmustine; Drug Synergism; Genetic Therapy; Glioma; Humans; I-kappa B Proteins; Irinotecan; NF-kappa B; NF-KappaB Inhibitor alpha; Repressor Proteins; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioblastoma; Glioma; Humans; Irinotecan | 2003 |
Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Safety | 2003 |
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Safety; Treatment Outcome | 2003 |
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Cell Movement; Chromones; Enzyme Activation; Enzyme Inhibitors; Glioma; Glycogen Synthase Kinase 3; Humans; Imidazoles; Immunohistochemistry; Integrin beta1; Laminin; Membrane Glycoproteins; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: implications for WRN function.
Topics: 4-Nitroquinoline-1-oxide; Adenine; Alkylating Agents; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinogens; Cells, Cultured; DNA Damage; DNA Helicases; DNA Replication; Drug Resistance; Exodeoxyribonucleases; Fibroblasts; Glioma; Guanine; Humans; Hydroxyurea; Netropsin; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotides, Antisense; RecQ Helicases; Werner Syndrome; Werner Syndrome Helicase | 2004 |
2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
Topics: Adenosine Triphosphate; Antimetabolites; Antineoplastic Agents, Phytogenic; Benzimidazoles; Brain Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cell Survival; Deoxyglucose; DNA Damage; Drug Interactions; Enzyme Inhibitors; Etoposide; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2004 |
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; RNA, Messenger; Transcription Factors; Vascular Endothelial Growth Factor A | 2005 |
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cricetinae; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Glioma; Humans; Mutation; Organosilicon Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cyclophosphamide; Cytochrome P-450 CYP2B1; Genetic Therapy; Glioma; Herpesvirus 1, Human; Humans; Irinotecan; Prodrugs; Virus Replication | 2005 |
Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
Topics: Antineoplastic Agents, Phytogenic; Brain Stem Neoplasms; Camptothecin; Child; Diarrhea; Female; Glioma; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Magnetic Resonance Imaging; Polymorphism, Genetic | 2005 |
High salt culture conditions suppress proliferation of rat C6 glioma cell by arresting cell-cycle progression at S-phase.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Early Growth Response Protein 1; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glioma; Hypertonic Solutions; Irinotecan; Osmolar Concentration; Rats; Resveratrol; S Phase; Sodium Chloride; Stilbenes | 2005 |
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Irinotecan; Paclitaxel; Structure-Activity Relationship; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vincristine | 2006 |
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Proliferation; Female; Fluorine Radioisotopes; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiography; Radiopharmaceuticals; Survival Rate; Thymidine | 2007 |
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate | 2008 |
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Glioma; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas.
Topics: Camptothecin; Cell Death; Cell Line, Tumor; Delayed-Action Preparations; Drug Screening Assays, Antitumor; Glioma; Glycerol; Humans; Isocyanates; Lysine; Microscopy, Electron, Scanning; Organosilicon Compounds; Polyurethanes; Prostheses and Implants; Solutions; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Tablets | 2008 |
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Enterohepatic Circulation; Female; Glioma; Half-Life; Humans; Irinotecan; Male | 2009 |
Determinants of drug response in camptothecin-11-resistant glioma cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Flow Cytometry; Glioma; Glutathione; Glutathione Transferase; Humans; Irinotecan; Nucleic Acid Conformation; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
[Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11].
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Glioma; Humans; Irinotecan; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Glioma; Humans; Irinotecan; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1993 |
Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin.
Topics: Antineoplastic Agents; Camptothecin; Chloramphenicol O-Acetyltransferase; DNA Replication; DNA Topoisomerases, Type I; Gene Expression Regulation, Viral; Glioma; Humans; JC Virus; Neuroglia; Promoter Regions, Genetic; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; Topotecan; Transfection | 1993 |
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Central Nervous System Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.
Topics: Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle Proteins; Cell Division; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; fas Receptor; Glioma; Humans; Immunotherapy; Naphthoquinones; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmustine; Child; Cyclophosphamide; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1998 |
Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Survival; COS Cells; DNA, Complementary; Glioma; Humans; Irinotecan; Liver; Molecular Sequence Data; Prodrugs; Rabbits; Sequence Alignment; Sequence Homology, Amino Acid; Tumor Cells, Cultured | 1998 |
Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation.
Topics: Brain Neoplasms; Camptothecin; Cell Survival; Colonic Neoplasms; DNA Damage; Drug Synergism; Etoposide; Glioblastoma; Glioma; Humans; Mitotic Index; Phosphotyrosine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Camptothecin; Cell Division; Cell Movement; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Genes, src; Glial Fibrillary Acidic Protein; Glioma; Membrane Glycoproteins; Mice; Mice, Transgenic; Neoplasm Invasiveness; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 1999 |
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Cell Death; Cell Division; Cisplatin; Clone Cells; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation, Neoplastic; Genes, Dominant; Glioma; Humans; In Vitro Techniques; Paclitaxel; Point Mutation; Radiotherapy; Teniposide; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vincristine | 1999 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Drug Synergism; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2000 |
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Division; Cisplatin; Drug Synergism; Female; Glioma; Growth Inhibitors; Humans; Medulloblastoma; Mice; Mice, Nude; Neuroectodermal Tumors, Primitive; Sirolimus; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; CDC2 Protein Kinase; Cyclin A; Cyclin B; Cyclin B1; Enzyme Inhibitors; G2 Phase; Gene Expression Regulation, Neoplastic; Glioma; Humans; Medulloblastoma; Neoplasm Proteins; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2001 |
Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Glioma; Rats; Rats, Wistar; Tumor Cells, Cultured | 2001 |
Altered irinotecan metabolism in a patient receiving phenytoin.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Interactions; Glioma; Humans; Irinotecan; Phenytoin; Topoisomerase I Inhibitors | 2002 |